DSM-5 and clinical trials in psychiatry: challenges to come?

The publication of the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in 2013 raises important questions for clinical trials and associated regulatory decisions on new drugs for psychiatric disorders.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2012-08, Vol.11 (8), p.583-584
Hauptverfasser:	Butlen-Ducuing, Florence, Haas, Manuel, Pani, Luca, van Zwieten-Boot, Barbara, Broich, Karl
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/109 692/700/1538 Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research Care and treatment Clinical trials Clinical Trials as Topic - methods Clinical Trials as Topic - trends comment Diagnosis Diagnostic and Statistical Manual of Mental Disorders Drug Design Humans Legislation, Drug Medicinal Chemistry Mental Disorders - classification Mental Disorders - diagnosis Mental Disorders - drug therapy Mental illness Methods Molecular Medicine Pharmacology/Toxicology Physiological aspects Practice Psychiatry Research Design
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The publication of the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in 2013 raises important questions for clinical trials and associated regulatory decisions on new drugs for psychiatric disorders.
ISSN:	1474-1776 1474-1784
DOI:	10.1038/nrd3811